Rate My Professor Graeme Milligan

With over 30 years of experience, Milligan's research centers on the structure, function, and regulation of G protein-coupled receptors (GPCRs) and their interacting proteins, translating fundamental insights into small molecule drug discovery for conditions such as diabetes, obesity, neuropsychiatric disorders, inflammation, and metabolic diseases. His work emphasizes receptors regulated by metabolic products, including free fatty acid receptors (FFA2, FFA3, FFA4) and orphan receptors (GPR35, GPR84). He has authored or co-authored more than 550 peer-reviewed publications, garnering over 35,000 citations, with seminal contributions including 'G protein-coupled receptor dimerization: function and ligand pharmacology' (2004), 'Heterotrimeric G-proteins: a short history' (2006), and recent works on GPR84 antagonists and FFA2 allosteric modulation. Milligan has edited key volumes such as 'G-Protein-Coupled Receptor Dimers' (2017) and 'Free Fatty Acid Receptors' (2017). His impact is recognized through awards including the Royal Society Mullard Award (2022) for pharmacological leadership and translational success, the British Pharmacological Society JR Vane Medal (2016) for molecular and signalling pharmacology, the Norwegian Poulsson Medal (1998), and the Dutch Ariens Medal (2006). He co-founded Caldan Therapeutics (2015) targeting metabolic diseases and Keltic Pharma Therapeutics (2020) for malaria treatments.